



Index

Page numbers in *italics* denote figures; those followed by a “t” denote tables; and those followed by a “c” denote capsules

A

- Abbott Sanitary Counting Tray, 257
Abbreviated New Drug Application
 bioavailability data, 177
 bioequivalence data, 185
 for generic drugs, 20
Abelcet injection, 740
Abortifacient, 753
Abradant, 753
Absorbent, 753
Absorption
 bases, for ointments, 317–318
 drug
 active transport, 121, 171–173, 409
 administration route and, 43, 47, 50, 61, 66, 167–169, 187–197, 334, 510, 625, 745, 768
 amorphous, 112
 area under curve representing, 183–184
 barriers, 66, 121, 166, 168–172, 192, 193, 307, 343, 345, 368, 369
 bioequivalence factors, 177–187
 controlled, 51, 175, 345, 349, 504, 514
 crystalline, 173, 175, 176, 276, 424, 550, 554
 dissolution and, 50, 51, 112, 117, 121, 172–177
 dosage form and, 43, 172–177
 in elderly persons, 197
 epicutaneous, 187t
 from extended-release products, 302, 309, 309
 facilitating diffusion, 171
 fate after, 172
 gastric emptying time, 172, 173, 183, 192, 274
 hydration state and, 177
 from injections, 194
 from liposomes, 740, 741
 membrane permeability and, 121
 nasal, 196
 ocular, 196
 otic, 196
 parenteral, 188t, 193
 particle size and, 112
 passive diffusion, 168–171
 percutaneous. *See* Transdermal drug delivery systems
 principles, 167
 protein binding and, 197, 204
 pulmonary, 197, 642, 710
 rate, 135, 135c–137c
 rectal, 188t, 192–193, 369–371
 in salt form, 177
 serum concentration and, 61, 183–184
 small intestinal, 172–177, 192, 368
 specialized transport mechanisms, 171–172
 surface area and, 174–175
 time course, 180
 transdermal. *See* Transdermal drug delivery systems
 urethral, 386–387
 vaginal, 735
 in packaging, 12
 Absorption, distribution, metabolism/
 biotransformation and excretion
 (ADME) studies, 47
 Abuse, drug regulations, 17
 Acacia, as emulsifying agent, 469
 Accelerated stability testing, 254
 Acesulfame potassium, 158
 Acetaminophen
 with codeine, 247
 rapidly dissolving tablet, 267
 in syrup, 416
 Acetazolamide, in nuclear medicine, 659
 Acid(s)
 diluted, 434–436
 dissociation constant, 124c
 pK_a values, 170t
 weak, solubility, 399t
 Acidification, of urine, 460t
 Acidifier, 753
 Acidifying agent, 151t
 Acquired immunity, 579
 Action letters, in new drug approval, 70
 Activated protein C, recombinant, 692
 Activation energy of, 454c
 Active immunity, 579–580
 Active ingredient, 763
 Active pharmaceutical ingredients
 definition, 83
 regulations, 129
 Active transport, 171
 Acute myeloid leukemia, gemtuzumab
 ozogamicin for, 683t
 Acute toxicity studies, 48
 Adalimumab (Humira), 700
 Additive properties, drugs, 517c
 ADD-Vantage System, for intravenous
 administration, 534, 534
 Adenocarcinoma, diagnostic imaging of,
 satumomab pentetide in, 705
 Adenosine deaminase (ADA)
 deficiency, gene therapy, 679
 Adenosine, in nuclear medicine,
 659–660
 Adhesive layer, in transdermal drug
 delivery systems, 349
 Administration routes
 dosage forms and
 parenteral, 188t, 193
 rectal, 188t, 192–193
 inhalation. *See* Inhalation
 administration route)
 nasal. *See* Nasal administration route
 ocular. *See* Ocular administration
 route
 oral. *See* Oral administration route
 otic. *See* Otic administration route
 for powders, 195
 rectal. *See* Rectal administration route
 sublingual, 188, 188t, 191
 for systemic effects, 187
 urethra, 188t, 197
 vaginal. *See* Vaginal administration
 route)
 Administration timing, dosage and, 66
 Adrenergic drug, 753
 Adrenocorticosteroids
 anti-inflammatory, 753
 salt-regulating, 753
 Adrenocorticotrophic hormone, 753
 Adsorbent, 151t, 753
 Adults, immunization schedules
 for, 603
 Adult-senior use packaging, 93, 93–94
 Advair Diskus, 229
 Adverse reactions
 product recall and, 24
 reporting, 35, 36, 56
 Advisory Committee on Immunization
 Practices, 578
 Aerosols, 763
 administration methods, 498–500
 advantages, 490–491
 compressed gas, 494
 containers for, 494–495
 definition, 488
 examples, 498, 499t
 filling of, 496–498
 foam, 763
 rectal administration, 500–501
 vaginal administration, 500–501
 inhalation
 examples, 498, 499t
 metered dose, 496
 particle size of, 175
 labeling, 498
 packaging, 498
 partial pressure and, 488c–489c
 particle sizes, 490
 powders, 227, 228, 500
 principles, 491–492
 product concentrate, 492
 propellants for, 151t
 blends, 493
 compressed gas, 494
 filling of, 496–498
 physical properties, 491t
 in three-phase systems, 493–494
 in two-phase systems, 493
 rectal, 500–501, 501t
 space, 493
 storage, 498
 surface, 493
 systems, 493
 testing, 498
 three-phase, 493–494
 topical, 500
 two-phase, 493
 vaginal, 500–501
 valve assembly of, 494
 Agar, as emulsifying agent, 469
 Age. *See also* Elderly persons; Pediatric
 patients
 in clinical studies, 54–55
 dosage form design, 104
 drug dosage, 62–63
 drug metabolism and, 200
 flavor preferences and, 152t
 gastrointestinal absorption and, 173
 Aggregation, of globules, 475–476
 Agitation, in syrup preparation, 418
 Agonist, 753

- Air
displacement of, 151t
humidifiers for, 627, 627–628
suspension tablet coating, 288–289, 288–289
- Airway, 228. *See also* Inhalation administration route
- Albumin, drug binding to, 197
- Alcohol
dehydrated, 401
diluted, 402
in pediatric patients, 406
as preservative
in syrups, 402
as solvents
in tinctures, 424
- Alcohol-abuse deterrent, 753
- Aldehyde dehydrogenase inhibitor, 753
- Aldesleukin (Proleukin), 682, 683t, 697–698
- Alendronate sodium tablets, 257
- Alginate acid, as gelling agent, 481
- Alkalinization
systemic, 411
of urine, 201
- Alkalinizer, 753
- Alkalinizing agents, 151t
- Alkylating agents, 753
- Allergic reactions
sulfites, 140
to vaccines, 591, 595
- All-in-one granulation methods, for
tablet manufacture, 279, 279–280
- Allogeneic tumor vaccines, 586
- Alloying substance, for tablet coatings, 287
- Alpha glucosidase inhibitor, 753
- Alpha particle, 640
- Alpha receptor agonist, 753
- Alpha receptor antagonist, 753
- Alpha reductase inhibitor, 753
- Alpha tocopherol as antioxidants, 140
- Alpha value, of drugs, 197
- Alprostadil, in urethral
microsuppository, 386–387
- Alteplase (Activase), recombinant, 706, 706–707
- Aluminum Acetate Topical Solution, 428
- Aluminum, for aerosol containers, 486
- Aluminum hydroxide
in antacids, 459, 462, 463
as gels, 485–486
in suspensions, 463
- Aluminum subacetate topical solution, 428
- Aluminum tubes, 325
- Alzet osmotic pump, 734–735
- AmBisome, 741
- Ambulatory care setting, pharmacy
practice in, 26
- Amebicide, 753
- American Association of Colleges of
Pharmacy Janus Commission,
pharmaceutical care statement, 29
- American Association of Pharmaceutical
Scientists, code of ethics, 31
- American National Standards Institute,
15
- American Pharmacists Association
code of ethics for pharmacists, 30–31
drug standards, 8–15
mission statement, 28
National Formulary of, 11
Nuclear Pharmacy Practice
Guidelines, 661
pharmaceutical care statement, 28
- American Society of Health System
Pharmacists (ASHP)
pharmaceutical care statement, 28
quality assurance guidelines, 543–544
- Amino acids, in parenteral nutrition,
563
- Ammonia, radiolabeled, in positron
emission tomography, 656–657
- Amorphous compounds, in dosage
form design, 112
- Amorphous forms, dissolution of,
175–177
- Amorphous polyethylene terephthalate
glycol (APET), 91
- Amoxicillin, USP, 13, 14
- Amphiphilic colloid, 479
- Amphotec, 741
- Amphotericin B liposome formulation,
741
- Ampicillin, anhydrous form, 177
- Ampuls, 763
definition, 523
filling and sealing of, 537, 538
for parenterals, 523
sizes of, 535
- Amyl nitrite
inhalation, 628
volatility, 106
- Anabolic steroid, 753
- Anakinra (Kineret), 698, 698
- Analeptic, 753
- Analgesics, 753
in ear preparations, 630
patient-controlled analgesia, 511
- Anaphylaxis, in vaccination, 591
- Andreasen pipette, in particle size
measurement, 218c
- Androderm patch, 348t, 355
- Androgen, 753
- Anemia, erythropoietin in, 690
- Anesthetics, for ophthalmic use, 607
- Angiotensin-converting enzyme
inhibitor (ACE) inhibitor, 43, 754
- Angle of repose, of powders, 218c–219c
- Anhydrous forms, dissolution, 177
- Aniline derivatives, as colorants, 158
- Animal powders, definition, 216
- Animals
drug sources, 39
drug testing
metabolism studies, 47
pharmacology studies, 46, 47
toxicology studies, 47–48, 49
- Anorexiant, 754
- Anorexic, 754
- Antacid, 754
chewable tablet, 282
side effects, 459
suspensions, 459, 462–463
- Antagonist, 754
- Anthelmintic drug, 754
- Anthrax
adsorbed vaccine, 588
in bioterrorism, 600–601
- Antiacne agent, 754
- Antiadrenergic, 754
- Antiamebic, 754
- Antiandrogen, 754
- Antianemic, 754
- Antianginal agent, 754
- Antiarrhythmic, 754
- Antiarthritic, 754
- Antibacterial, 754
- Antibiotics, 754
in ear preparations, 632
in frozen form, 535
- lyophilization, 533
manufacturing, 533
in ophthalmic preparations, 607
in suspension, 464
- Antibody(ies)
chimeric, 704
human antimouse, 677
man-made, 677
monoclonal. *See* Monoclonal
antibodies
- Anticholesterol agent, 754
- Anticholinergic agents, 754
gastrointestinal absorption and, 173
- Anticholinesterase antidote, 754
- Anticoagulants
antagonist, 754
from biotechnology, 685
- Anticonvulsant, 754
- Antidepressant, 754
- Antidiabetic drug, 754
- Antidiarrheal drug, 754
- Antidiuretic drug, 754
- Antidote, 754
for radiation exposure, 658, 658–659
- Antidyskinetic drug, 755
- Antieczemetic drug, 754
- Antiemetic drug, 755
- Antiepileptic drug, 755
- Antiestrogen, 755
- Antifibrinolytics, 755
- Antifilarial drug, 755
- Antiflatulent, 755
- Antifungal agents, for ophthalmic use,
532, 607
- Antifungal preservative, 151t
- Antigens
lymphocyte recognition of, 579
skin, diagnostic, 601–602
tumor associated, in vaccine
preparation, 585
- Antiglaucoma agent, 755
- Antigonadotropin, 755
- Antigout agent, 755
- Antihemophilic drug, 755
- Antihemophilic factors (Kogenate,
Recombinate), 686–687
- Antih herpes agent, 755
- Antihistamines
elixirs, 421–423, 422t
syrups, 413t
- Antihyperlipidemic drug, 755
- Antihypertensive drug, 755
- Antihypocalcemic drug, 755
- Antihypoglycemic drug, 755
- Anti-infective drug, 755
- Anti-inflammatory drug, 755
- Antileishmanial drug, 755
- Antileprotic drug, 755
- Antilipemic drug, 755
- Antimalarial drug, 755
- Antimanic drug, 755
- Antimetabolite, 755
- Antimicrobial preservative, 151t
- Antimigraine agent, 755
- Anti-motion sickness agent, 755
- Antimuscarinic drug, 755
- Antinauseant drug, 755
- Antineoplastic drug, 755
- Antineuritic drug, 755
- Antiparasitic drug, 755
- Antiparkinsonian (antidyskinetic) drug,
755
- Antiperistaltic drug, 755
- Antiplatelet agent, 755
- Antiprogesterin, 756
- Antiprotozoal, 756

- Antipruritic drug, 756
 Antipsoriatic drug, 756
 Antipsychotic drug, 756
 Antipyretic drug, 756
 Antirachitic drug, 756
 Antiretroviral drug, 756
 Antirheumatic drug, 756
 Antirickettsial drug, 756
 Antischistosomal drug, 756
 Antiscorbutic drug, 756
 Antiseborrheic drug, 756
 Antisecretory agent, 756
 Antisense technology, 679
 Antispasmodic drug, 756
 Antithyroid agent, 756
 Antitreponemal, 756
 Antitrichomonal drug, 756
 Antitubercular drug, 756
 Antitussive drug, 756
 Antivenins, 587, 590
 Antiviral agents
 for ophthalmic use, 607
 prophylactic, 632
 Antiviral drug, 756
 Antixerophthalmic drug, 756
 Anxiolytic drug, 756
 Apothecary, first, 5
 Apothecary system, 770, 772–773, 777
 Apparent density, of powders, 219c
 Appearance, of pharmaceutical ingredients and excipients, 150, 151t
 Aqueous film-coating, 287
 Area under the concentration-time curve, bioavailability assessment, 178
 Aromas, for tablets, 287
 Aromatic water, 763
 Arthritis, rheumatoid
 adalimumab for, 700, 700
 anakinra for, 698, 698
 Artificial colloids, 479
 Artificial sweeteners, 158
 Artificial tears, 607–608
 Ascorbic acid, antioxidant, 140
 Ascorbyl palmitate, antioxidant, 140
 Aseptic, definition, 763
 Aseptic processing, 763
 Aspartame, 158
 Aspirin
 absorption, 173
 bioavailability, in suppositories, 366
 Association colloid, 479
 Asthma, omalizumab, 703
 Astringent, 756
 ophthalmic use, 607
 Atomizers, 426
 Atropine, sodium chloride equivalent of, 610–611, 611t
 Attenuated vaccines, 580
 Auger electron, 641
 Aural, 763
 Autoclave, in parenteral sterilization, 522
 Autoinjection systems, 749, 749–750
 Autologous tumor vaccines, 585–586
 Automation, for drug manufacture, 82–83, 83, 84
 Autoxidations, in drug degradation, 134
 Avoirdupois system, 770, 773
 Avonex (interferon beta-1a), 696
- B**
- B lymphocytes, in immunity, 579
 Bacille Calmette-Guérin (BCG), USP, 586
 Backing layer, transdermal drug delivery systems, 350
 Bacterial endotoxins test, USP, 531
 Bacterial filtration
 of ophthalmic preparations, 606
 of parenterals, 524
 Bacterial vaccine, 583, 589t–591t
 Bacteriostatic sodium chloride injection, USP, 516
 Bacteriostatic water for injection, USP, 516
 Balance
 electronic, 776–778
 prescription, 776–778
 Barbiturate, 423, 756
 Barium hydroxide, in pyrogen removal, 531
 Barium sulfate suspension, 463–464
 Base(s)
 for ointments, 317–318
 pKa values, 170t, 192
 suppositories
 bioavailability and, 371
 classification, 372
 determination of amount required, 378–382
 Basiliximab (Simulect), 700–701
 Batch, definition, 78
 Batchwise control, definition, 78
 Beads, coated, for extended-release products, 303, 303
 Becaplermin (platelet-derived growth factor) (Regranex), 694
 Becquerel, 640
 Beeswax, as hardening agent, 373
 Belladonna alkaloid, 756
 Bentonite, as emulsifying agent, 470
 Bentonite magma, NF, 485
 Benzalkonium chloride
 as emulsifying agents, 470
 as preservative, 608
 Benzodiazepine, 756
 Benzoic acid, 322, 399t, 484
 Beta particles, 641
 Beta receptor agonist, 756
 Beta receptor antagonist, 756
 Beta-blockers, 510
 for ophthalmic use, 607
 Betaseron (interferon beta-1b), 695–696
 Bile, drug excretion, 200
 Binders, for tablets, 264
 Binding sites, for drugs, 207
 Binding, to plasma proteins, 197
 Bingham bodies, 454c
 Bioanalytical research laboratories, 210
 Bioavailability
 area under serum concentration time curve, 183–184
 assessment, 180–181
 in capsule products, 245
 concentration time curve, 183–184
 definition, 185
 FDA submission requirements, 179
 intranasal, 629
 in ophthalmic preparations, 616
 of oral drugs, factors affecting, 186t
 peak height, 181–182
 time of peak, 182–183
 Bioavailable fraction
 first-pass effect, 187
 formula for, 187
 Bioequivalence
 absolute, 183
 assessment, 180–184
 definition, 177
 differences, 178
 factors affecting, 186t
 of generic drugs, 185
 standards, 185
 Bioequivalent drug products, definition, 184
 Biologic characterization, of drugs, 44–50, 46, 47
 Biologic indicators, of sterilization effectiveness, 527
 Biologic membrane, drug penetration of, 168
 Biologicals, 578–604
 for active immunity, 583–586
 administration, toxicity associated with, 587–600
 animal immune sera, 587, 588t–591t
 antitoxins, 587, 590t
 antivenins, 587, 590t
 bioterrorism and, 600–601
 case studies, 602–603
 definition, 578
 diagnostic skin antigens, 601–602
 examples, 588t–591t
 expiration date, 581
 handling, 581–583
 human immune sera and globulins, 587
 immunity and, 578–581
 labeling, 581
 mixed, 583, 586
 for passive immunity, 587, 588t–591t
 production, 581
 shipping, 581–583
 side effects, 587, 591
 storage, 581–583
 toxoids, 580, 586, 589
 vaccines. *See* Vaccines and vaccination
 Biologics license applications, 72
 Biopharmaceutics, 166
 Biotechnology products
 anticoagulants, 685
 antisense drugs, 679
 case studies, 721–723
 classification, 682
 clotting factors, 682
 colony stimulating factors, 687–689, 688
 definition, 672
 erythropoietins, 690–693
 Food and Drug Administration office on, 713–714
 fusion inhibitors, 693–694
 future, 711–713
 growth factors, 695
 human DNase 1, 710–711, 711
 human growth hormone, 694
 interferons, 695–696
 interleukins, 696–699
 patient education on, 693–694
 pharmacist information on, 714, 715, 716, 717t–720t
 production
 gene therapy in, 678–679
 monoclonal antibodies in, 699–706
 nucleotide blockade/antisense technique, 679
 peptide technology, 679
 polymerase chain reaction in, 678
 recombinant DNA techniques, 674–676
 protein-based, advantages, 711
 rasburicase, 710
 reimbursement issues, 716
 tissue plasminogen activators, 706–708
 tyrosine kinase inhibitors, 708–710
 vaccines, 709–710

- Bioterrorism, 600–601
 Biotransformation. *See* Metabolism, drug
 Bisacodyl, in suppositories, 367t
 Bisphosphonate, 756
 Bitter taste, 157
 Black box warnings, 18
 Blending, of powders, 223–225, 224–225
 Blinded studies, 51–52, 58
 Blister packaging, 91
 Blood, isotonicity, 609
 Blowers, for powders, 228, 228
 Board of Pharmaceutical Specialties, 26–27
 Body fluids, isotonicity, 609
 Body membranes, classification, 168
 Body surface area, dosage determination and, 64, 65
 Body weight, dosage determination and, 64
 Boiling point, of mixtures, 517
 Bolus, 763
 Bone disease, radiopharmaceuticals in, 647
 Bone marrow, granulocyte macrophage colony-stimulating factor for, 687–688
 Bone metabolism regulator, 756
 Boric acid
 in ear preparations, 631
 in ophthalmic preparations, in tonicity considerations, 610
 Bottle (Forbes) method, 474–475
 Bottom spray method, for tablet coating, 289
 Botulism antitoxins, 590
 Botulism, in bioterrorism, 600, 601
 Brain imaging
 drug interference with, 667t
 positron emission tomography, 658
 Brain, tumor resection in, carmustine implant for, 745, 745–746, 746
 Breast cancer, trastuzumab for, 705
 Breast-feeding, radiopharmaceuticals during, 668
British Pharmacopoeia (BP), 8
 Bronchodilator, 756
 Brookfield Viscometer, 450, 450
 Broviac catheter, for repeated injection, 513
 Buccal system, mucoadhesive testosterone, 733–734
 Buccal tablets, 265–266
 Buffer capacity, 138, 138c–140c
 Buffering agent, 151t
 drug stability, 138
 ophthalmic preparation, 612
 Buildings, for drug manufacture, regulations on, 79
 Bulk powders, 229–230
 Bulk volume, of powders, 219c–220c
 Bulkiness, of powders, 219c
 Butyl hydroxy anisole, as antioxidant, 140
- C**
 Calamine Liniment, 475
 Calcium carbonate, 451, 459, 462
 Calcium channel blocker, 756
 Calcium hydroxide solubility, 397
 topical solution, 397
 Calcium, in parenteral nutrition, 563
 Calcium soaps, emulsion preparation, 475
 Calibration, of suppository molds, 378
 Caloric requirements
 in enteral nutrition, 565
 in parenteral therapy, 562
 Cancer
 detection, satumomab pendetide in, 705
 interleukins for, 696–699
 pain in, fentanyl lollipop for, 293
 positron emission tomography, 654
 rituximab for, 704
 trastuzumab for, 705–706
 vaccines for, 585–586
Candida albicans skin test antigen, 591t, 602
 Caplets, 190, 763
 Capping defect, in tablets, 281, 282
 Capromab pendetide (ProstaScint), in prostate cancer, 649–650
 Capsules, 763
 case studies, 259–261
 colorants for, 240, 247
 commercially available, 255, 255t
 compendial requirements, 251–254
 content uniformity, 254
 counting, 255–256, 257
 definition, 240
 dilutents for, 244, 245
 disintegrants for, 244
 disintegration test for, 251–252
 dispensers for, 251
 dissolution test for, 252–253
 extended-release
 coated particles in, 240
 glidants for, 245, 247
 hard gelatin
 cleaning, 249, 252
 contents of, examples, 247
 design, 242–243, 243
 dissolution, 241
 drug absorption from, 241
 filling, 247–249, 248, 249
 formulations for, 244–247, 245
 gelatin properties, 243
 liquids in, 246
 manufacturing, 241–243, 242, 243
 passage of, tracking methods, 241
 polishing, 249, 252
 preparation, 243–244
 sealing, 249, 252
 sizes, 244, 244, 245
 small capsules or tablets inserted into, 245
 swallowing, 241
 transit time, 241
 uses, 240
 weight variation, 254
 identification, 239
 inspection, 255–256, 257
 labeling, 254
 lubricants for, 245, 247
 moisture permeation test for, 254–255
 official, examples, 255–256, 255t
 opaquants for, 247
 opening, 242, 243, 256
 for oral use, 256
 overview, 240
 packaging, tamper-evident, 249
 rectal, 388
 soft gelatin
 preparation, 250–251, 253, 254
 utilization, 251
 weight variation, 253–254
 stability testing, 254
 storage, 255–256, 257
 substances added to, 251
 swallowing, 239, 240
 vaginal, 388
 weight variation, 253–254
 wetted, 241
 Captopril, in nuclear medicine, 659
 Carbamide peroxide
 cerumen-removing solutions, 630
 dental solutions, 433
 Carbohydrates
 as emulsifying agents, 469
 requirements, in enteral nutrition, 565
 Carbomer resins, 482
 Carbon dioxide, radiolabeled, in positron emission tomography, 657
 Carbon-11, in positron emission tomography, 656
 Carbonic anhydrase inhibitor, 756
 Carbowaxes, 481
 Carcinoembryonic antigen detection, radiopharmaceuticals in, 643
 Carcinogenicity studies, 49
 Cardiac depressant, antiarrhythmic, 757
 Cardiac glycoside, 757
 Cardiotonic, 422t
 Carmustine implant, after brain tumor resection, 745, 745–746, 746
 Cascade impaction, particle size measurement, 221
 Castor oil emulsion, 477
 Catapres TTS, 347t, 353
 Catecholamine synthesis inhibitor, 757
 Catheter
 Broviac/Hickman, 513
 central venous, 513
 indwelling plastic, 513
 Cauterizing agent, 757
 Caventou, Joseph, 7
 Cavitation, in phonophoresis, 731
 Cell cultures, in preclinical testing, 44–45
 Center for Biologics Evaluation and Research, 56, 581
 Center for Drug Evaluation and Research, 23, 56, 541
 Centipoise, 615
 Centistokes, 615
 Central compartment, in pharmacokinetics, 204
 Central vein parenteral nutrition (central vein TPN), 565
 Central venous catheters, 513
 Centrally acting drug, 757
 Cephalosporin, 757
 Certification
 colorants, 158
 finished pharmaceuticals, 78
 pharmacist, 27
 Cerumen-removing solutions, 630
 Cesium, radioactive, exposure to, antidote for, 658, 658–659
 Chelating agent, 152t, 757
 Chemical abstracts service (CAS) registry number, 12
 Chemical enhancers, transdermal drug delivery systems, 344
 Chemotherapy
 bone marrow, granulocyte macrophage colony-stimulating factor for, 687–688
 drugs for, safe handling, 543
 Gliadel Wafer, 745, 745–746, 746
 neutropenia in, granulocyte colony-stimulating factor, 687–688
 thrombocytopenia in, oprelvekin for, 698
 Chewable tablets, 266

- Children. *See* Pediatric patients
- Child-resistant packaging, 93–94, 94
- Chimeric antibodies, 704
- Chloramphenicol, crystalline *vs.* amorphous, 175
- Chloride, in oral rehydration solutions, 410
- Chlorobutanol, as preservative, 162, 609
- Chlorofluorocarbons, in aerosols, 491
- Cholelitholytic, 757
- Cimetidine
discovery, 41, 42
in nuclear medicine, 659
- Citric acid
in effervescent granulated salts, 232, 233c–234c
sodium citrate and, 411
- Clarifying agent, 152t
- Cleaning solutions, for contact lenses, 621–623
- Clearance, drug, 207
- Clinical studies
controls, 58–59
designs, 58–60, 60
drug dosage and terminology, 59–66, 60, 61, 62t, 63t, 65
phases, 56–58, 57t, 58
clinical trial materials, regulations, 84
- Clonidine, transdermal drug delivery systems, 347t, 353–354
- Clotting factors, recombinant, 686–687
- Code of Federal Regulations* (CFR), 23
- Collodion, 764
- Colloidal dispersion, 764
- Colloidal silicon dioxide, 483
- Colony-stimulating factors, recombinant, 687–690
- Color Additive Petition, for contact lens manufacture, 621
- Colorants, 152t
capsules, 160
certification status, 158
for contact lenses, 621
formulation, 160
lake pigments, 160
powdered drug, 160
for tablets, 160
- Comminution, of drugs, 222–223, 223
- Compliance
finished pharmaceuticals, 78
packaging for, 94
- Components, drug product
definition, 78
regulation, 83
- Comprehensive Drug Abuse Prevention and Control Act of 1970, 16, 17
- Compressed tablets. *See* Tablets, compressed
- Concomitant drug therapy, 66
- Contact lenses
advantages, 620
care, 621
cleaners for, 621–622
clinical considerations, 623–624
color additives to, 621
combination solutions for, 623
disadvantages, 620
disinfecting solutions for, 622
disposable, 620
drug interactions, 623
extended wear, 620
hard, 620
neutralizing solutions for, 622
rigid gas permeable, 620
rinsing solutions for, 622
soaking solutions for, 545, 623
soft, 621–622
storage solutions for, 622
types, 620
wetting solutions for, 623
- Containers, 79–80
for aerosols, 494–495
definition, 80
for packaging, 88–93, 89, 90, 91t, 543
regulations, 83
- Continental (dry gum) method, 473
- Contraceptives, 757
oral, 745
transdermal, 355
vaginal preparations, 735, 735
- Corticosteroid, 757
- Coupling agents, for phonophoresis, 730
- Creams, 764
definition, 323
dermatologic, 327–329, 330t, 331t, 332t
packaging, 325–326
rectal, 334–335, 336t
vaginal, 336, 336–337, 336t
- Cresol, as preservative, 162
- Crinone gel, 737
- Crohn disease, infliximab for, 702
- Crossover designs
for bioequivalence studies, 178
clinical studies, 58–59, 60
- Cross-tolerance, 66
- Crystalline structure, 106
dissolution of, 173
- Crystals, polymorphism of, 176
- Cups, for measuring doses, 776
- Curie, 640
- Current Good Compounding Practices, 85–88
- Current Good Manufacturing Practice for active pharmaceutical ingredients, 83
for biologics, 84
for clinical trial materials, 84
for finished pharmaceuticals automation, 82–83, 83, 84
control of components, containers, and closures, 79–80
distribution procedures, 81
equipment, 79
facilities, 77t, 79
general provisions, 76–78
holding procedures, 81
information technology, 82–83, 83, 84
labeling control, 80–81
laboratory controls, 81–82
organization, 78–79
packaging control, 80–81, 82t
personnel requirements, 78–79
process controls, 80
production controls, 80
records management and reports, 82
returned drug products, 82
salvaged drug products, 82
for labeling, 94–97
for manufacturing in pharmacies, 85
for medical devices, 84–85
noncompliance with, 85
for packaging, 88–93, 89, 90, 91t
for pharmaceutical excipients, 83
standards, 76, 76t
for storage, 97
for transportation, 97
- Cycloplegic drug, 757
- Cyclotron, in radiopharmaceutical production, 657, 662
- Cystic fibrosis, human DNase I for, 710
- Cytomegalovirus (CMV)
immunoglobulin, 590t
retinitis, fomivirsen, 685
- D**
- Daclizumab (Zenapax), 701
- Darbepeotin alfa (Aranesp), 691–692, 692
- Decongestant, 757
- Delayed-release products
definition, 301
drug release rate from, 309, 309
enteric coatings, 307
examples, 307t
- Demulcent, 757
- Dental caries prophylactic drug, 757
- Dentin desensitizer, 757
- Depigmenting agent, 757
- Detergent, 757
- Diagnostic aid, 757
- Diagnostic imaging
radiopharmaceuticals for, 642, 642–643
satumomab pendetide in, 704
- Dietary Supplement Health and Education Act (DSHEA) of 1994, 21–22, 96
- Diffusion
coefficient, 118–119c, 169, 484, 738
facilitated, 171
layer, 172
passive, 168–171
- Digestive aid, 757
- Digoxin
discovery, 8
dosage regimen for, 201
in elixirs, 424
half-life, 201
- Diluents, for capsules, 244, 245
- Dinoprostone, in vaginal insert, 736, 737
- Dipyridamole, in nuclear medicine, 659–660
- Disinfectant, 757
- Disinfection, of contact lenses, 622
- Diskhaler inhalation device, 229
- Disposable contact lenses, 620
- Dissociation constants
in dosage form design, 123
passive diffusion, 169
- Dissolution
of amorphous forms, 175–177
hydration state and, 177
of salt form, 177
- Diuretic drug, 757
- Diuretics
loop, 561, 660, 759
potassium-sparing, 561, 760
thiazide, 201, 761
- Diverticulum, Meckel's, nuclear imaging of, 659
- Divided powders, 230
- DNA technology, recombinant, in biotechnology products, 674–676
- Dopamine receptor agonist, 757
- Dosage form(s), 764
administration routes, 66
nasal, 196
ocular, 196
oral, 196
otic, 196
parenteral, 188t, 193
rectal, 188t, 192–193
novel. *See* Novel dosage forms and drug delivery systems

- Dosage form design
 biopharmaceutical considerations
 passive diffusion, 168–171
 specialized transport mechanisms, 171–172
 general considerations
 microscopic examination, 107
 oral dosage devices, 104, 105
 various forms, 104, 104
 importance, 160
 low usual doses, 189t
 pharmaceutical ingredients and excipients
 appearance, 156
 palatability, 156–161
 types, 150, 151t–155t, 155
 preformulation studies
 complex organic molecules, 131, 131c–133c
 dissolution, 117–118, 118c–120c
 heat of vaporization, 107, 107c–108c
 hydrates and solvates, 124–125, 125c
 melting point depression, 108, 109c
 membrane permeability, 121
 microscopic examination, 107
 organic ester considerations, 128, 128c–129c
 organic salt considerations, 126–127, 127c
 particle size, 112
 partition coefficient, 121, 121c–123c
 pH, 161
 phase rule, 108, 110c–111c
 physical description, 106–107
 pKa/dissociation constants, 123, 123c–124c
 polymorphism, 112
 potency-designated active pharmaceutical ingredients, 129–130, 130c–131c
 solubility, 112
 stability considerations
 accelerated stability studies, 147–150, 148c–149c
 degradation mechanism and, 134
 drug product, 134–135
 drug substance, 147
 enhancement, 137–142, 138c–140c
 excipient, 147
 expiration date, 147
 kinetics, 134–135
 Q₁₀ method of shelf life estimation, 137
 rate reactions, 135, 135c–137c
 shelf life, 137
 stress testing, 147
 testing, 147–148
- Dressing, 764
- Drops
 eye. *See* Ophthalmic preparations
 nasal, 628–629
- Drotrecogin alfa (activated) (Xigris), 692–693, 693
- Drug(s)
 administration routes. *See* Administration routes
 chemical properties, 104
 definition, 2
 delivery system, 764
 discovery. *See* Drug discovery and drug design
 early, 5–6, 6
 formulations, 4
 homeopathic, 12
 interactions with food, 177
 legend, 16
 loading of, in rapidly dissolving tablets, 267
 new. *See* New drug(s)
 pharmacy, heritage of, 4–8
 physical properties, 104
 regulation. *See* Drug regulation and control
 semisynthetic, 38
 uses, 2
- Drug discovery and drug design, 3
 FDA's definition, 43–44
 goal drug in, 40
 lead compound (prototype) in, 41–43
 methods, 40–41
 nomenclature and, 44
 prodrugs in, 43
 sources of new drugs, 38–40
- Drug Enforcement Administration, 17
 Drug Listing Act of 1972, 18, 20
- Drug Price Competition and Patent Term Restoration Act of 1984, 20–21
- Drug product, definition, 78
- Drug product recall, 24
- Drug regulation and control
Code of Federal Regulation. See Code of Federal Regulations
 Comprehensive Drug Abuse Prevention and Control Act of 1970, 16, 17
 Dietary Supplement Health and Education Act (DSHEA) of 1994, 21–22
 Drug Listing Act of, 18, 20
 Drug Price Competition and Patent Term Restoration Act of 1984, 20–21
 drug product recall, 24
- Durham-Humphrey Amendment of 1951, 16
- Federal Food, Drug, and Cosmetic Act of 1938, 15–25
- Food and Drug Administration
 Modernization Act of 1997, 22–23
- Kefauver-Harris Amendments of 1962, 16–17
- Prescription Drug Marketing Act of 1987, 21
- Dry powder inhaler, 764
- Durham-Humphrey Amendment of 1951, 16
- E**
- Ear, drug administration to. *See* Otic administration route
- Early formulation studies, 50–52
- Effervescent dosage form, 764
- Effervescent granulated salts, 232, 232c–234c
- Elderly persons
 absorption in, 197
 in clinical studies, 54–55
 dosage form design for, 105
 drug dosage for, 459
 gastrointestinal absorption in, 169
 packaging for, 94
 protein binding in, 197
- Electrical current, in iontophoresis, 728
- Electroendosmotic flow, in iontophoresis, 729
- Elimination, drug, 200, 201
- Elixirs, 764
 antihistamine, 421–423, 422t
 barbiturate, 423
 components, 420
 definition, 420
 digoxin, 424
 medicated, 421
 nonmedicated, 421
 phenobarbital, 423–424
 preparation, 421
 proper administration and use, 425
vs. syrups, 420
 theophylline, 420
- Emetic drug, 758
- Empirical approach, to dosage regimen, 208
- Emulsifying agent, 152t
- Emulsions, 764
 aggregation, 475–476
 coalescence, 475–476
 creaming, 476
 definition, 465
 examples, 477–478
 fat, intravenous, 196
 injectable, 560
 inversion, 470
 oil-in-water, 465
 oral, 477
 packaging, 476
 phases, 476
 preparation
 bottle (Forbes) method, 474–475
 continental (dry gum) method, 473
 emulsifying agents for, 468–470
 English (wet gum) method, 473
 foam, 501
 HLB system in, 470, 471c–472c
 homogenizer in, 473
 mechanical blender in, 470
 microemulsion, 475
 mortar and pestle in, 451
 in situ soap method, 475
 preservatives for, 476
 purpose, 465–466
 stability, 475–476
 temperature and, 476
 theories of emulsification, 466–468, 467c–468c
 topical, 477–478
 water-in-oil, 465
- Enalapril
 metabolites of, 199
 as prodrug, 43
- Encapsulating agent, 152t
- Endothelin receptor antagonist, 758
- Enema, 764
- Enfuvirtide (Fuzeon), 693, 693–694
- English (wet gum) method, 473
- Enzyme, 758
- Epicutaneous administration route, 187t
- Epidermal growth factor, 758
- Epinephrine, autoinjection systems, 749, 749–750
- Ergot alkaloid, 758
- Erythropoietins, recombinant, 690–693
- Estradiol, transdermal drug delivery systems, 347t, 354–355
- Estring vaginal drug delivery system, 735, 736
- Estrogen, 758
- Eutectic mixtures
 capsules, 246
 of powders, 223
- Expectorant, 758
- Expiration date
 for biologics, 581
 for finished pharmaceuticals, 81
- Extended-release products
 advantages, 300, 301t
 chemical complexes, 305

- coated beads, granules, or microspheres, 303, 303
 definition, 299, 301
 disadvantages, 300
 drug candidates, 302
 drug release rate from, 309, 309
 embedded in matrix system, 304–305
 examples, 307t
 ion exchange resins, 305–306
 microencapsulated drug, 304, 304
 multitablet system, 303
 oral, 302–307, 303–304, 306
 osmotic pump, 306, 306–307
 rationale for, 300
 repeat-action tablets, 307
 transdermal. *See* Transdermal drug delivery systems
 in vitro/in vivo correlations, 309–310
- F**
- Facilitated diffusion in, 171
 Factor VIII (ReFacto), recombinant, 687, 687
 Feathering method, in pharmacokinetics, 205
 Fecal softener, 758
 Federal Food, Drug, and Cosmetic Act of 1938
 Comprehensive Drug Abuse Prevention and Control Act of 1970, 17
 Durham-Humphrey Amendment of 1951, 16
 Kefauver-Harris Amendments of 1962, 16–17
 Fentanyl
 in lollipops, 293
 transdermal drug delivery systems, 347t–348t
 Fertility agent, 758
 Fick's laws, 168
 First-order kinetics, 169
 Flavorant, 152t
 Flavoring pharmaceuticals, 156–158
 Flexible colloidion, 433, 437
 Foam, 765
 Food
 drug interactions with metabolism and, 177
 oral administration timing, 256
 Food and Drug Administration
 Current Good Manufacturing Practice, 52, 68, 70, 76, 88, 142
 drug classification system, 56
 Modernization Act of 1997, 22–23, 85
 pregnancy categories, 18
 Forbes bottle method, 474–475
 Furosemide, in nuclear medicine, 660
 Fusion inhibitors, recombinant, 693–694
 Fusion method
 for effervescent granule preparation, 232–235
 ointment preparation, 321–322
 Fusion protein, special handling, 743–744
- G**
- GABA agonist, 758
 Gastric acid secretion inhibitor, 758
 Gastroprokinetic drug, 758
 Gel(s), 765
 classification, 480–481, 480t
 colloidal, 478–479
 definition, 478
 dermatologic, 334t
 examples, 484–487
 formulation considerations, 484–485
 gelling agents for, 481–484
 lubricating jelly, 487
 nasal, 333–334
 ophthalmic, 329, 331–333, 334t
 packaging, 322
 preparation, 481
 principles, 478
 single-phase, 478
 terminology, 479–480
 two-phase. *See* Magmas vaginal, 336, 737
 Gelatin, 483
 Gender
 clinical studies, 54
 dosage determination, 64, 66
 Gene therapy, 40
 in biotechnology production preparation, 678–679
 General anesthetic, 196
 Gliadel Wafer, 745, 745–746, 746
 Globule, 765
 Glucocorticoid, 758
 Glutamate inhibitor, 758
 Glycerogelatin, 325–326
 Gonadotropin, 758
 Goserelin (Zoladex), 746–747
 Granules, 765
 clinical case study, 236–237
 definition, 215
 effervescent, 233c–234c
 dry or fusion method, 234
 wet method, 234–235
 flow properties, 232
 particle size, 216
 pharmaceuticals case study, 235–236
 preparation, 231, 231–232
 Granulocyte colony-stimulating factor monomethoxypolyethylene glycol (pegfilgrastim), 689, 689
 recombinant (Filgrastim), 687–689, 689
 Granulocyte macrophage colony-stimulating factor, recombinant, 689–690
 Gray, as radiation unit, 640
 Growth factor, recombinant, 694
 Growth hormone, 758
 human, 39, 675, 683t, 694–695
 recombinant, 694
Guide to the Inspection of Bulk Pharmaceutical Chemicals, 83
 Gum, 765
- H**
- Haemophilus influenzae* vaccines
 recombinant (HibTITER, PedvaxHIB, ActHIB), 709–710
 Half-life
 of drugs
 vs. total body clearance, 207
 of radioisotopes, 639–640
 Hard-shell capsule, 765
 Heavy metal antagonist, 758
 Hematinic drug, 758
 Hemorrhagic agent, 758
 Heparin, thrombocytopenia induced by, lepirudin for, 685
 Hepatitis B vaccine (Engerix-B, Recombivax HB), 709
 Hirudin, recombinant, 685
 Histamine H₁ receptor antagonist, 758
 Histamine H₂ receptor antagonist, 758
 HMG-CoA reductase inhibitor, 758
 Hormone, 758
 Human DNase I, recombinant (Pulmozyme), 710–711, 711
 Human growth hormone, recombinant, (Protropin, Humatrope), 694–695, 695
 Human immunodeficiency virus (HIV) infection
 efavirenz for, 686
 enfuvirtide for, 694
 Humectant, 152t
 Hybridoma technology, for monoclonal antibodies, 676
 Hydantoin, 758
 Hydration state, dissolution and, 177
 Hydrocortisone
 in ear preparations, 630
 phonophoresis of, 731
 in suppositories, 367t
 Hydrolytic drug, 759
 Hydrophilic ointment, 317
 Hydrophilic petrolatum, 317
 Hydrophilic-lipophilic balance (HLB) system, 740
 Hyperglycemic drug, 759
- I**
- Ibritumomab tiuxetan (Zevalin), in non-Hodgkin lymphoma, 650, 650, 702
 Imbibition, of gel, 479–480
 Immunizing agent, 759
 Immunoglobulin, 759
 Immunoglobulin G
 monoclonal antibody preparation from, 676
 placental transfer of, 580
 Immunosuppressant, 759
 Implants, 744–748, 745, 746, 765
 in brain tumor resection cavity, 745, 745–746, 746
 goserelin in, 746–747
 Indium-111 chloride, 649–651, 650
 Information technology, in drug manufacture, 82–83, 83, 84
 Infusion, 765
 Inhalant, 765
 Inhalation, 766
 Inhalation administration route aerosols
 examples, 499t
 metered dose, 496–498
 inhalants, 550, 628
 powders, 227, 228
 solutions, 628
 Initial product formulations, 51–52
 Injections, 766
 intravenous injections
 advantages, 510
 automated, 511
 disadvantages, 517
 flow rates for, 510
 history, 509–510
 infusion devices for, 566–567
 procedure, 511
 transfer of additives to, 522
 volumes of, 547
 procedure, 511
 safe systems for, 750
 veins for, 510
 Intropic agent, 759
 Inserts
 ophthalmic, 737–739, 738
 vaginal, 736, 737

- Insulin
 autoinjection systems, 749, 749–750
 crystalline vs. amorphous, 175–176
 Interferons, recombinant, 695–696, 743
 Interleukins, recombinant, 696–699
 International Conference on
 Harmonization of Technical
 Requirements for Registration of
 Pharmaceuticals for Human Use
 (ICH), 73
 International Organization for
 Standardization, 15
 Intrauterine devices, 735–736, 736, 766
 Intravenous injections
 advantages, 510
 automated, 511
 disadvantages, 517
 flow rates for, 510
 history, 509–510
 infusion devices for, 566–567
 procedure, 511
 transfer of additives to, 522
 veins for, 510
 volumes of, 547
 Investigational New Drug Application
 clinical protocol, 54–56
 clinical studies
 controls, 58–60
 designs, 58–59, 60
 drug dosage and terminology,
 59–66, 60, 61, 62t, 63t, 65
 phases, 56–58, 57t, 58
 content, 53
 drug classification, 56
 FDA review, 56
 meetings before, 56
 for orphan drug, 67
 termination, 67
 treatment, 67
 withdrawal, 67
 Ion exchange resins, 305–306, 759
 Iontophoresis, 344
 Irrigation, 766
 Irritant, 759
- J**
- Jars, ointment, 326
 Jejunostomy feeding tube, 266
 Jelene, 481
 Jelly(ies), 766
 lubricating, 487
 Jet milling, for suspensions, 451
- K**
- Kefauver-Harris Amendments of 1962,
 16–17
 Keratolytic drug, 759
 Kidney
 drug excretion, 200
 radiopharmaceuticals for, 642, 642
 Kinematic viscosity, 615
 Kineret, 698, 698
 Kinetic approach, to dosage regimen,
 208
King's Guide to Parenteral Admixtures, 559
- L**
- Labeling
 dietary supplement label, 96–97, 97
 manufacturer's, 94–95
 over-the-counter (OTC) drugs,
 95–96, 96
 of prescription container, 95
 storage conditions on, 97
 Lacrisert system, 737–738
 Lactation, 18
 Lactinex granules, 22–23
 Lanolin, 318
 Laxative, 759
 Leaching, from plastic packaging, 92
 Lead compound (prototype), 41–43
 Length, units
 intersystem conversion of, 773
 metric system, 770–773
 Lepirudin (Refludan), 685
 Leukemia, acute myeloid, gemtuzumab
 ozogamicin for, 683t
 Leukotriene receptor antagonist, 759
 Levigating agent, 152t
 Levigation, for particle size reduction,
 223
 Liniment, 766
 Lipase inhibitor, 759
 Liposomes, 739–742, 766
 advantages, 740
 amphotericin formulation with, 741
 configurations for, 740
 daunorubicin formulation with, 741
 description, 739
 disadvantages, 740
 doxorubicin formulation with, 742
 examples, 741
 preparation, 739–740
 stealth, 740, 742
 Lipstick, 766
 Liquid(s), 766
 measurement techniques, 776–780
 quantitative product strength, 774–775
 volume measurement, 778–780
 Liquid preparations. *See also* Solutions
 advantages, 160
 in capsules
 hard gelatin, 246
 soft gelatin, 371
 dosage forms for, 103
 flavorants for, 160
 incorporation into ointments, 319,
 319–321, 320, 321
 for nuclear medicine. *See*
 Radiopharmaceuticals
 oral administration, 103, 103t
 packaging, 24
 Lotion, 766
 Lozenge, 766
 Lung
 drug administration to, 187t
 aerosolized powders for, 227–228,
 228
 drug excretion, 200
 inhalation solutions for, 625–628, 627
 Lung surfactant, 759
 Lymphoma, non-Hodgkin's
 radiopharmaceuticals in
 rituximab for, 689
 Lyophilization, 766
- M**
- Magmas
 bentonite, 485
 definition, 478
 preparation, 481
 principles, 478
 Magnesium aluminum silicate, 483
 Manufacture, liposomes, 739–742
 Mathematical models, for
 compartmental analysis, in
 pharmacokinetics, 202
 Medical devices, good manufacturing
 practice standards for, 95
 Melting point, depression of, 108, 109c
 Metabolism, drug, 47
 active metabolites from, 168
 examples, 190t
 factors affecting, 200
 first-pass effect, 187
 first-pass effect in, 47
 pathways, 200
 time course, 180
 Metal complexing agent, 759
 Methylcellulose, 483
 Methylphenidate, transdermal drug
 delivery systems, 356
 Metric system, 770–773
 Microemulsions, 475
 Microstreaming, in phonophoresis, 731
 Milk of magnesia, 486
 Mineralocorticoids, 759
 Minimum fill test, 322
 Modified-release products
 case studies, 311–313
 clinical consideration, 310–311
 definition, 299, 301
 driving forces, 299
 examples, 307t
 labeling, 310
 oral, 302–307
 packaging, 311
 storage, 311
 terminology, 301
 uniformity of dosage units, 309
 USP requirements, 309, 309–310
 in vitro/in vivo correlations, 309–310
 Molded tablet, 766
 Monoamine oxidase inhibitor, 759
 Monoclonal antibodies, 759
 in clinical practice, 699
 preparation, 702
 radiolabeled, 645
 toxic protein fusion with, 708
 Mouthwash, 766
 Mucoadhesive testosterone buccal
 system, 733–734
 Muromonab-CD3 (Orthoclone OKT3),
 703
 Muscle relaxant, 759
 Mydriatic drug, 759
- N**
- Narcotic antagonist, 759
 Narcotic drug, 759
 Nasal administration route, 624–630
 for decongestants, 625
 drops for, 628–629
 inhalants for, 628
 inhalation solutions for, 625–628, 627
 ointments for, 333–334
 preparations for
 examples, 624–625, 625, 626t
 procedures, 629–630
 sprays for, 628–629
 for systemic effects, 629–630
 National Association of Boards of
 Pharmacy, compounding
 practices of, 87–88
National Formulary, monographs, 11–12,
 86
 Natural colloids, 479
 Needles, safe systems for, 750
 Nernst-Planck equation, in
 iontophoresis, 728
 Neuraminidase inhibitor, 760
 Neuromuscular blocking agent, 760

- New drug(s)
 biologic characterization, 44–50, 46, 47
 clinical trial materials, 51–52
 development, overview, 34–37, 35, 36
 FDA-approved, standards in, 22
 formulations for, 50–52
 metabolism, 47
 pharmacology, 45–47, 46
 preformulation studies, 50–51. *See also*
 Preformulation
 toxicology, 47–50, 49
- New drug application
 abbreviated, 72
 action letters, 70
 for animals, 72–73
 annual reports on, 71–72
 Biologics License Applications, 72
 drug product labeling, 69–70
 FDA review, 70
 for medical devices, 73
 NDA submission, 68–69
 phase 4 studies, 70–71
 postmarketing activities, 71
 supplemental, 72
- Nicotine, transdermal drug delivery systems, 347t, 354
- Nitroglycerin
 administration route, 187
 sublingual, 187
 transdermal drug delivery systems, 345, 347t, 352–353
- Noncompliance
 with manufacturing regulations, 85
 patient, factors associated with, 94
- Nonsteroidal anti-inflammatory drug, 760
- Novel dosage forms and drug delivery systems, 726–751
 autoinjection systems, 749, 749–750
 benefits, 727
 drug composition for, 727
 fusion protein, 743–744
 implants, 744–748, 745, 746
 iontophoresis, 728–729, 731, 732, 732t, 733t
 liposomes, 739–742
 mechanisms, 727
 microspheres, 748
 mucoadhesive system, 733–734
 ophthalmic, 737–739, 738
 oral, 733–735
 osmotic pump, 734, 734–735
 parenteral, 739–742, 739t
 pegylated dosage forms, 742–743
 phonophoresis, 729–731
 safe-needle systems, 750
 subgingival, 748, 749
 topical, 727–733, 730, 731, 732t–733t
 vaginal, 735–737
- Novobiocin, crystalline *vs.* amorphous, 175
- Noyes-Whitney equation, 173
- Nuclear medicine. *See*
 Radiopharmaceuticals
- Numby Stuff iontophoresis system, 729
- O**
- Ocular administration route, 196
- Ointments, 152t, 766
 bases for, 317–318
 definition, 316
 dermatologic, 316, 327–329, 328, 330t, 331t, 332t
 hydrophilic, 317
 labeling, 322
- microbial content, 322
 minimum fill test, 322
 nasal, 333–334
 ophthalmic, 329, 331–333, 334t
 packaging, 322
 polyethylene glycol in, 318
 preparation, 319, 319–322, 320, 321
 preservatives for, 318, 322, 324, 335
 rectal, 334–335, 335, 336t
 requirements, 322–323
 storage, 322
 vaginal, 336–337, 336t
 white, 317
 yellow, 317
- Omnibus Budget Reconciliation Act of 1990 (OBRA 90), 30
- One-compartment model, for pharmacokinetics, 207
- Open-model system, 202
- Ophthalmic preparations
 buffering, 612–615, 615t
 case studies, 633–634
 clarity, 617
 for contact lens, 623
 with contact lens wear, 620, 623
 contact lens-related, 623
 drug delivery from, 606–607
 gels, 329, 331–333, 334t
 inserts, 737–739, 738
 isotonicity, 609–612, 612t
 novel, 737–739, 738
 ointments, 329, 331–333, 334t
 packaging, 617, 617
 pH, solubility and, 613c–614c
 retention time, 607
 sterility, 608, 608–609
 thickening agents for, 615–616
 viscosity, 615–616
- Opioid, 760
- Opioid antagonist, 760
- Oprelvekin (Neumega), 698–699, 699
- Oral administration route
 absorption
 capsules for, 188t
 solutions for, 188t
 suspensions for, 188t
 tablets for, 188t
 osmotic pump formulations for, 734–735
- Organogels, 481
- Orphan drugs, Investigational New Drug Application withdrawal, 67
- Osmotic pump drug delivery system, 734–735
- Otic administration route, 630–632
 procedures, 632
 solutions for, 630–632, 631t
 analgesic, 630–632
 anti-infective, 630–632
 anti-inflammatory, 630–632
 cerumen-removing, 630
 suspensions for, 632
- Otic suspension, 767
- Ovulation stimulator, 760
- Oxytocic drug, 760
- P**
- Packaging
 child-resistant, 93–94, 94
 compliance, 94
 containers for, 88–93, 89, 90, 91t
 glass, 91, 91t
 light-resistant, 90
 strip, 90, 90
- Parasympatholytic drug, 760
- Parasympathomimetic drug, 760
- Parenterals
 administration routes
 intradermal, 195, 513
 intramuscular, 194, 511–512
 intravenous, 194–195
 specialized access, 513
 subcutaneous, 194
 subcutaneous route, 512–513
 case studies, 573–575
 chemotherapeutic, handling and disposal, 571
 dialysis solutions, 571–572
 drug adsorption, 526
 frozen, 535
 implants, 513
 irrigation solutions, 571
 labeling, 535–542
 large-volume
 administration, 543
 caloric requirements, 562–563
 electrolyte requirements, 561–562
 examples, 572t
 incompatibilities, 559
 intravenous infusion devices for, 566–567
 for maintenance therapy, 560–561
 manufacturing, 532
 for nutrition, 563–565
 packaging, 535–542
 for replacement therapy, 561
 transfer of additives to, 522
 water requirements, 561
 long-acting, 514, 739, 739t
 look-alike products, 569
 manufacturing
 antibiotics, 532
 clarity in, 537
 contaminant exclusion in, 537
 drug colligative properties and, 517c–521c
 dry, 524
 environment for, 542–543
 for extemporaneous compounding, 555
 liquid with powder, 532
 packaging in, 535–542
 quality assurance, 543–544
 suspensions, 532
 novel drug delivery system, 739–742, 739t
 official types, 513–514
 pellets, 566
 pyrogen removal and testing, 531
 small-volume
 advantages, 547
 disadvantages, 547
 examples, 545t–546t
 insulin, 548–558
 manufacturing, 550
 precautions with, 547–548
 solvents for, 514–516
 special considerations, 567–571
 sterilization, 522–526
 storage, 535–542
 substances added to, 521–522
 vehicles for
 aqueous, 514
 nonaqueous, 516–517, 517c–521c
 volume overages, 541
- Particle size, of powders, 216–217, 216t
- Partition coefficient, in dosage form design, 121, 121c–123c
- Passive diffusion, 168–171
- Pastes, 324–325, 767
- Pastille, 767

- Patches
for transdermal drug delivery, 357. *See also* Transdermal drug delivery systems (TDDSs)
- Pathologic state, dosage and, 64
- Pediatric patients
in clinical studies, 55
drug dosage for, 60, 62–63
packaging resistant to, 93–94, 94
suppositories for, 386
suspensions for, 456
total nutrient admixtures, 559
- Pediculicide, 760
- Pegylated dosage forms, 742–743
- Pellet, 767
- Penicillin adjuvant drug, 760
- Penicillin G, crystalline *vs.* amorphous, 175
- Pennkinetic system, sustained-release suspensions, 457
- Percutaneous absorption. *See* Transdermal drug delivery systems (TDDSs)
- Pessaries. *See* Suppositories, vaginal
- Petrolatum, 317
- pH, in passive diffusion, 170
- Pharmaceutical alternatives, definition, 184
- Pharmaceutical care, definition, 28–29
- Pharmaceutical equivalents, definition, 184
- Pharmaceutical measurement
errors in
significance, 770
volume, 779
weight, 776
systems for
apothecary, 770, 772, 773, 777, 778
avoirdupois, 770, 773
conversion among, 770
dosage units, 774, 775
formula reduction and enlargement, 775
household, 775–776
metric, 770, 771, 773
quantitative product strength, 774–775
techniques
volume, 778–780
weight, 777
- Pharmacist, contemporary role, 26–30
- Pharmacogenetics, 63–64
- Pharmacokinetics
definition, 167
principles, 167
- Pharmacopeias, 8–15
- Pharmacy
early research, 7–8
heritage of, 4–8
mission, 28
practice standards, 29–30
school of
first, 8
scientific viewpoint introduced, 6–7
- Phase 4 clinical studies, 70–71
- Phase rule, in dosage form design, 108, 110c–111c
- Phenothiazine, 760
- Phonophoresis, 729–731
- Photosensitizer, 760
- Pigmenting agent, 760
- Pilocarpine, insert, 738, 738–739
- pK_a (dissociation constants), in dosage form design, 123, 123c–124c
- Plasma volume expander, 760
- Plasters, 325, 767
- Plastibase, 480
- Plasticizer, 152t
- Plastics, in packaging, 91
- Plateau concentration, of drug, 203
- Platelet growth factor, 760
- Platelet-derived growth factor, recombinant, 694
- Platelet-reducing agent, 760
- Pledge, 767
- Poloxamers, 374, 483
- Polymorphism, dosage form design, 112
- Posterior pituitary hormone, 760
- Potassium-sparing diuretic, 760
- Potentiator, 760
- Poultice, 767
- Povidone, 483
- Powders, 767
angle of repose, 218c–219c
blending, 223–225, 224–225
blowers for, 228, 228
bulkiness, 219c
clinical case study, 236–237
comminution of, 222, 223
definition, 215
density, 220c
flow properties, 218c
granule preparation from, 230–232, 231
medicated
aerosol, 227, 228
bulk, 229–230
divided, 230
particle size and, 216–217, 216t
pharmaceutics case study, 235–236
porosity, 219c
volume, 219c
- Preformulation studies
complex organic molecules, 131, 131c–133c
dissolution, 50, 117–118, 118c–120c
heat of vaporization, 107, 107c–108c
hydrates and solvates, 124–125, 125c
melting point depression, 108, 109c
membrane permeability, 121
microscopic examination, 107
organic ester considerations, 128, 128c–129c
organic salt considerations, 126–127, 127c
particle size, 112
partition coefficient, 50, 121, 121c–123c
pH, 161
phase rule, 108, 110c–111c
physical description, 106–107
physical form, 50–51
 pK_a /dissociation constants, 123, 123c–124c
polymorphism, 112
potency-designated active pharmaceutical ingredients, 129–130, 130c–131c
solubility, 50, 112
stability, 51
- Pregnancy, 18
- Prescription Drug Marketing Act of 1987, 21
- Preservatives
general considerations, 162
mode of action, 162
selection, 161–162
with sterilization, 161
- Process validation, definition, 78
- Procrit (epoetin alfa), 690–691
- Prodrugs
absorption, 43
biostability, 43
prolonged release, 43
solubility, 43
- Progesterone
in vaginal insert, 735–736, 736
in vaginal suppositories, 374, 387
- Progestin, 760
- Prostaglandin synthetase inhibitor, 760
- Protease inhibitor, 760
- Proteasome inhibitor, 760
- Protectant, 760
- Prothrombogenic drug, 760
- Proton pump inhibitor, 761
- Psychedelic drug, 761
- Psychotherapeutic drug, 761
- Pump, osmotic, 734–735
- Q**
 Q_{10} method of shelf life estimation, 137
- Quality assurance
definition, 78
for parenterals, pharmacy-prepared, 543–544
for radiopharmaceuticals, 663–664
- Quality audit, definition, 78
- Quality control, definition, 78
- Quality control unit, definition, 78
- Quantitative product strength, 774–775
- Quarantined area, 78
- R**
Rabies vaccines, 589t
- Racial immunity, 579
- Radiation
exposure, drug antidote for, 658, 658–659
ionizing, in parenteral sterilization, 526
- Radiogardase, for radiation exposure, 658, 658
- Radiographic agent. *See* X-ray contrast medium
- Radioimmunotherapy, 643
- Radionuclides, definition, 639
- Radiopaque agent, 761
- Radiopharmaceutical drug, 761
- Radiopharmaceuticals, 638–670, 767
applications, 638–639
background information, 639–642
case studies, 668–669
consultation on, 666, 666t, 667t
definition, 638
dispensing, 664–665
distribution, 665
dosage units for, 640
drug interference with, 666t, 667t
education on, 666
examples, 645, 646t
gallium-67 citrate, 649
harmful exposure to, antidote for, 658–659
holmium-166, 653
indium-111 chloride, 649–651, 650
labeling, 662
lutetium-177, 653
monoclonal antibodies, 643
nonradioactive drugs used with, 659–660
outcome monitoring, 667–668
physics, 639–642
in positron emission tomography, 653–658, 657t
practice guidelines, 660–668
preparation, 662–663, 663

- procurement, 661–662
 production, 641
 quality assurance, 663–664
 regulatory process, 668
 rhenium-186/188, 653
 rhenium-HEDP, 653
 safety, 665–666
 samarium-153, 652–653
 sodium iodide (I-123), 651
 sodium iodide (I-131), 651–652
 storage, 661–662
 strontium-89 chloride, 647
 targeting strategies, 639, 643
 technetium-99m, 645–647
 thallos-201 chloride, 648, 648–649
vs. traditional drugs, 639
 uses
 diagnostic, 642, 642–643
 therapeutic, 643–645
 yttrium-90, 647–648, 648
- Random screening, in drug
 discovery, 40
- Ranitidine (Zantac), mechanism-based
 design, 41
- Rapidly dissolving tablets, 267–268, 268
- Rasburicase (Elitek), 710
- Rate reactions, 135, 135c–137c
- Rate-controlled delivery. *See also*
 Modified-release products
 definition, 301
 Ratio strength, 774, 775
- Rauwolfia alkaloid, 761
- ⁸²Rb, in positron emission tomography,
 656
- Reaction order, 135
- Reaction rate, 135
- Recall, of drug products, regulations, 24
- Receptor sites, for drugs, 45, 46, 198
- Recombinant DNA technology
 for biotechnology products, 674–676
 in drug preparation, 39
- Reconstitution
 of dry forms, 138
 of powders, for suspensions, 464
- Rectal administration route, 188t,
 192–193
 aerosols for, 335, 500–501, 501
 creams for, 334–335, 336t
 ointments for, 334–335, 335, 336t
 solutions for, 431
 suppositories, 386
 drug absorption from, 369–371
 examples, 367t, 386
 local action, 368–369
 systemic action, 369
 suspensions for, 464–465
- Rectal fluids, buffering capacity, 370
- Reduction, 199
- Refrigeration, of hydrolysis prone
 drugs, 138
- Registered pharmacist (RPh), 26
- Regulation, of drugs. *See* Drug
 regulation and control
- Rehydration solutions, oral, 410
- Remicade, 702–703
- Renal cell carcinoma, aldesleukin for,
 683t
- Renal disease, erythropoietin in, 683t
- Renal transplantation
 basiliximab in, 701
 daclizumab in, 701
 muromonab-CD3 in, 703
- Repeat-action tablets, 307
- Replacement therapy, parenterals, 561
- Repository injections, 193
- Representative sample, definition, 78
- Reprocessing, definition, 78
- Reproduction studies, 49
- Research, in early times, 7–8
- Reserpine, sources, 38
- Residency programs, for pharmacists,
 27
- Resin, electrolyte removing. *See* Ion
 exchange resins
- Respiratory stimulant, 761
- Respiratory syncytial virus infection,
 palivizumab for, 704
- Retention enemas, 432
- Retention time, ophthalmic
 preparations, 607
- Retepose (Retavase), recombinant, 707
- Reticuloendothelial system,
 radiopharmaceuticals in, 646–647
- Retinitis, CMV, fomivirsen for, 685
- Retinoic acid derivative, 761
- Returned drug products, regulations, 82
- Reverse iontophoresis, 729
- Reverse osmosis, 404
- Review clock, for new drug approval, 70
- Rhenium-186/188, 653
- Rhenium-HEDP, 653
- Rheology, 452
- Rheumatoid arthritis
 adalimumab for, 700
 anakinra for, 698
- Rigid gas permeable contact lenses, 620
- Ringer's injection, USP, 558t
- Ringer's irrigation, USP, 572t
- Rings, vaginal, 735, 736
- Rinse, 767
- Rinsing solutions, for contact
 lenses, 622
- Rituximab, ibritumomab tiuxetan
 (Zevalin) in non-Hodgkin
 lymphoma, 689
- RNA, antisense, 679
- Robiquet, Pierre, 7
- Robotic devices, 83, 83
- Roller compaction, for granule
 preparation, 279–280
- Rotary die process, for capsule
 preparation, 250, 253, 254
- Rotary tablet press, 281
- Rotavirus vaccine, 594t
- Rubbing alcohol, 402
- Rubefacient, 761
- Rubella vaccine, 589t
- S**
- Salicylic acid collodion, 437–438
- Salts
 dissolution, 177
 substitute, 761
- Salvaged drug products, regulations, 82
- Scabicide, 761
- Sclerosing agent, 761
- Scopolamine, transdermal drug delivery
 systems, 348t
- Sedative, 761
- Selective estrogen receptor modulator
 (SERM), 761
- Sepsis, drotrecogin alfa (activated) in,
 692
- Serotonin agonist, 761
- Serotonin antagonist, 761
- Simethicone emulsion, 477
- Smoking deterrent, 761
- Sodium alginate, 484
- Sodium iodide (I-123), 651
- Sodium iodide (I-131), 651–652
- Soft gel capsule, 767
- Solubility
 particle size, 113
 pH, 113, 115c–117c
- Solutions, 767. *See also* Solubility;
 Solvents
 colligative properties, 610
 definitions, 396
 elixirs, 420–424, 422t, 424
 inhalation, 628
 irrigation, 571, 572t
 ophthalmic
 administration, 617–618, 618t–619t
 for contact lens use, 621–622
 drug delivery from, 606–607
 examples, 618t–619t
 packaging, 617, 617
 pharmaceutical requirements, 608,
 608–617, 611t, 612t, 613c–614c,
 615t
 types, 607
 oral
 colonic lavage, 410
 examples, 427t–428t
 magnesium citrate, 410–411
 rehydration, 409–410
 sodium citrate with citric acid, 411
 syrups, 411–412
 otic, 630
 parenterals, 514
 preparation, 438–441
 proper administration and use, 425
 rectal, 431–432
 sorption tendency, 93
 strength, 434
 syrups, 411–420
 topical, 425–431
 vaginal, 431–432
- Solvents, 153t
 for extraction, 401–404
 glycerin, 402
 isopropyl rubbing alcohol, 402
 "like dissolves like," 399
 for parenteral, 403
 propylene glycol, 402
 selection, 401
 in tinctures, 424–425
 water, 404
- Somatostatin analog, 761
- Sonophoresis, 344
- Sorption, in packaging, 93
- Space sprays, 490
- Spatulation, in powder blending,
 223–225, 224–225
- Specialized transport mechanisms,
 171–172
- Spirits, 767
- Sponge, 768
- Steady state concentration, of drug, 209
- Stealth liposomes, 740, 742
- Sterility, 768
- Sterilization, preservatives with, 161
- Stick, 768
- Stiffening agent, 153t
- Stimulant, 761
- Stool softener, 761
- Storage, labeling information for, 97
- Strength, definition, 78
- Striant mucoadhesive testosterone
 buccal system, 733–734
- Strip packaging, 90, 90, 768
- Strontium-89 chloride, 647
- Sulfonylurea, 761
- Sunscreening agent, 761
- Suppositories
 appearance, 365, 366
 base, 153t

Suppositories (*continued*)

- bases for
 - bioavailability and, 371
 - classification, 372
 - determination of amount required, 378–382
 - case studies, 391–392
 - cathartic, 367t, 386
 - definition, 365
 - density (dose replacement)
 - calculations for, 379c–382c
 - glycerin, 368, 374, 386
 - hemorrhoidal, 369, 386
 - insertion
 - rectal, 365
 - vaginal, 367t, 388
 - local action, 368–369
 - packaging, 384
 - pediatric, 386
 - preparation
 - dose calculation for, 379c–382c
 - by hand rolling and shaping, 383
 - by molding, 377–379
 - rectal, 386
 - drug absorption from, 369–371
 - examples, 367t, 385
 - local action, 368–369
 - systemic action, 369
 - requirements, 383
 - storage, 384
 - systemic action, 369
 - urethral, 386–387
 - appearance, 365
 - bases for, 374
 - local action, 368–369
 - vaginal
 - appearance, 386
 - bases for, 365, 374
 - examples, 367t, 387
 - local action, 368–369
 - progesterone, 374, 387
 - systemic action, 369
- Suppressant, 761
- Surface area, of drug, dissolution and, 174–175
- Surface sprays, 490
- Surfactant, 153t
- Suspending agent, 153t
- Suspensions, 768
 - administration, 447
 - advantages, 446
 - antacid, 459, 462–463
 - antibacterial, 463
 - case studies, 502–505
 - definition, 446
 - desirable features, 455
 - dispersed phase, physical features, 450–451
 - dispersion medium for, 451–452, 452c–456c
 - drug interactions with, 495
 - extemporaneous compounding, 458–459
 - flocculated, 451
 - injectable, 458
 - ophthalmic
 - administration, 617–618, 618t–619t
 - for contact lens use, 621–622
 - drug delivery from, 606–607
 - examples, 618t–619t
 - packaging, 617, 617
 - pharmaceutical requirements, 608, 608–617, 611t, 612t, 613c–614c, 615t
 - types, 607
 - oral
 - examples, 459, 462–463
 - powders for, 464–465

- otic, 446
 - packaging, 459
 - parenteral, 451
 - powders for, 464–465
 - preparation, 456–458
 - rectal, 463–464
 - sedimentation rate in, 448–450, 448c–449c
 - storage, 459
 - sustained-release, 457–458
 - viscosity, 457
- Sweeteners
 - artificial, 158
 - comparison of, 153t
- Swelling, of gel, 479
- Syneresis, of gel, 479
- Syrups, 768
 - agitation, 418
 - colorants for, 418
 - components of, 412–415
 - vs. elixirs, 411
 - flavorants for, 418
 - heating of, 418–419
 - medicated, 412t, 419
 - nonmedicated, 412t
 - percolation, 419–420
 - preparation, 418–420
 - preservatives for, 415
 - proper administration and use, 425
 - sorbitol-base, 415
 - sucrose-based, 415
- Systemically acting drug, 761

T

- Tablets, 768
 - antiadherents, 153t
 - aromas for, 287
 - binders for, 154t, 264
 - buccal (sublingual), 265–266
 - capping defect, 281, 282
 - capsule diluent, 154t
 - capsule opaquant, 155t
 - case studies, 294–297
 - chewable, 266
 - coating agent, 154t
 - colorants for, 287
 - commercially available, 290, 291t
 - compressed
 - all-in-one granulation methods for, 279, 279–280
 - dedusting of, 282, 283
 - direct compression method for, 281–282, 282
 - dry granulation method for, 279–280, 280
 - effervescent, 266
 - enteric-coated, 265
 - film-coated, 265
 - gelatin-coated, 265
 - manufacture, 276
 - multiple, 264–265, 265
 - punch method for, 280–281, 281
 - quality standards for, 270, 270
 - rapidly-dissolving, 267–268, 268
 - shapes, 270, 270
 - sugar-coated, 265
 - Wet granulation method for, 276–279, 277–278- compression-coated, 289–290, 290
- content uniformity, 271
- dedusting of, 282, 283
- direct compression excipient, 154t
- disintegrant, 154t
- disintegrants for, 264
- dispensing, 266
- dissolution test for, 274–275, 275–276
- effervescent, 266
- enteric-coated, 288
- extended-release, 269
- fillers for, 276
- film-coated, 265
- flavorants for, 287
- fluid-bed coating of, 288, 288–289
- glidant, 155t
- glidants for, 234
- glossants for, 287
- hardness, 271–272, 272–273
- hypodermic, 266
- immediate-release, 267
- imprinting of, 286, 286
- inspection of, 271, 271
- lubricants for, 155t, 264
- manufacture
 - all-in-one granulation methods for, 279, 279–280
 - changes in, 290
 - coated, 284–290
 - direct compression method for, 281–282, 282
 - dry granulation method for, 279–280
 - quality standards for, 270, 270
 - molded (trituated), 266, 283, 283–284
 - official, examples, 290, 291t
 - opaquants for, 287
 - oral administration, 293
 - packaging, 292, 293
 - polishing agent, 155t, 286, 286
 - rapidly-dissolving (instant-release), 267–268, 268
 - repeat action, 281, 285
 - scored, 263, 270, 270
 - sealing coats for, 285
 - splitting defects, 282, 282
 - storage, 292, 293
 - subcoating, 285, 285
 - sugar-coated, 284–285, 284–285
 - sweeteners for, 287
 - thickness, 271, 272
 - vaginal, 269–270
 - waterproofing, 285
 - weight, 271, 271
- Tamper-evident packaging, 81
- Technetium-99m, 642, 645–647
- Teratogens, 19t
- Terminal sterilization, 768
- Testosterone
 - mucoadhesive buccal system, 733–734
 - transdermal drug delivery systems, 355–356
- Thallium, radioactive, exposure to, antidote for, 658
- Therapeutic dose, 62, 62t
- Therapeutic equivalents, 184
 - nicotine, 354
 - nitroglycerin, 345, 349, 350, 352–353
 - scopolamine, 352
 - testosterone, 355–356
- Therapeutic index, of drugs, 62, 62t
- Therapeutic window, of drugs, 62
- TheraSphere, 647, 648
- Thixotropy, 479
- Thrombocytopenia
 - chemotherapy-related, oprelvekin for, 698
 - heparin-induced, lepirudin for, 685
- Thrombolytic enzyme, 761
- Thyroid hormone, 761
- Tinctures, 768
 - benzoin, 425, 432–433
 - definition, 424
 - iodine, 432
 - thimerosal, 433
 - topical, 432–433

- Tolerance, drug, 66
- Topical preparations
- iontophoresis for, 728–729, 731, 732, 732t, 733t
 - phonophoresis for, 729–731
 - solutions
 - aluminum acetate, 428
 - aluminum subacetate, 428
 - calcium hydroxide, 397
 - chlorhexidine gluconate, 430
 - coal tar, 429
 - examples, 406
 - hydrogen peroxide, 429–430
 - povidone-iodine, 430
 - sprays, 426, 428
 - thimerosal, 430–431
- Topically acting drug, 761
- Toxicology
- acute or short-term toxicity studies, 48
 - carcinogenicity studies, 49
 - genotoxicity or mutagenicity studies, 49–50
 - reproduction studies, 49
 - subacute or subchronic studies, 48–49
- Tragacanth gum, 484
- Tranquilizer, 762
- Transdermal drug delivery systems (TDDSs), 768–769
- absorption in, 343–344
 - advantages, 351–352
 - case studies, 358–360
 - clinical considerations, 356–357
 - clonidine, 353–354
 - contraceptives, 355
 - definition, 342
 - design features, 346–351, 347t–348t, 350, 351, 353
 - disadvantages, 351–352
 - enhancement, 344
 - estradiol, 347t, 354–355
 - examples, 351, 352–356, 353
 - factors affecting, 343–344
 - fentanyl, 347t
 - historical aspects, 342–343
 - layers in, 346
 - membrane-controlled, 349, 351
 - methylphenidate, 356
 - monolithic, 346, 349
 - in vitro studies, 345, 345, 346
 - in vivo studies, 344–345
- Transdermal matrix patch, 769
- Transdermal membrane patch, 769
- Transderm-nitro transdermal therapeutic system, 349, 349
- Transplantation
- basiliximab in, 701
 - daclizumab in, 701
 - muromonab-CD3, 703
- Transportation, on labeling, 97
- Trastuzumab (Herceptin), 705–706
- Tricyclic antidepressant, 762
- Trituration
- particle size reduction, 216–217, 216t
 - in powder blending, 223–225, 224–225t
- Two-compartment model, for pharmacokinetics, 204
- Tyrosine kinase inhibitor, 708, 708–709
- U**
- United States Pharmacopeia*
- compounding monographs, 86–87
 - and *National Formulary*, 8–11
 - powder particle size, 216
- United States Pharmacopeial Convention*, 9–11
- Urea cyclic disorder agent, 762
- Uricosuric drug, 762
- Urinary acidifier, 762
- Uterine contractant, 762
- Uterine contraction inhibitor, 762
- V**
- Vaccines and vaccination
- active, 579–580
 - administration, nasal, 598
 - attenuated, 580, 583
 - bacterial, 583, 589t–591t
 - benefits, 578
 - bioterrorism and, 600–601
 - cancer, 585–586
 - definition, 578
 - handling, 581–583
 - immunity and, 578–581
 - inactivated, 580, 583
 - labeling, 581
 - mixed, 583, 586
 - in pregnancy, 580
 - production, 581
 - shipping, 581–583
 - side effects, 583, 585, 587
 - storage, 581–583
 - strength, 583
 - subunit, 583
 - suppositories for, appearance, 386
 - toxoids, 580, 586, 589
 - viral, 583–585, 589t–591t
- Vaginal administration route, 192
- aerosols for, 337, 500–501
- gels for, 737
- inserts for, 736, 737
- novel preparations for, 735–737
- preparations for, 334t, 336, 336–337, 336t
- rings for, 735, 736
- suppositories for, 367, 387, 387–388
- bases for, 373
 - local action, 368–369
 - progesterone, 374
 - systemic action, 369
- tablets for, 269–270
- Vaginal tablet/insert, 769
- Validation, 769
- definition, 78
- Validation protocol, definition, 78
- Valve assembly, of aerosols, 494
- Van der Waals forces, in solubility, 397
- Vapor pressure, of mixtures, 517c–518c
- Vaporizers, for inhalation therapy, 627, 627
- Varicella virus vaccines, 589t
- Vasoconstrictors, 762
- for ophthalmic use, 607–608, 624
 - with subcutaneous injections, 194
- Vasodilators, 762
- with subcutaneous injections, 194
- Vasopressor, 762
- Veegum, as gelling agent, 483
- Vegetable oils, as injection vehicles, 517
- Vegetable powders, definition, 216
- Vehicles, 155t, 769. *See also* Water isotonic phosphate, for ophthalmic preparations, 615, 615t
- for parenterals
 - aqueous, 514
 - nonaqueous, 516–517, 517c–521c
 - sterile, 155t
- Ventriculography, radiopharmaceuticals in, 642–643
- Verapamil, metabolism, 199
- Verified documentation, definition, 78
- Versacount Model automatic tablet and capsule counting and filling apparatus, 258
- Vesicant, 762
- Vinblastine, sources, 38
- Vinca alkaloid, 762
- Vincalukoblastine, discovery, 8
- Vincristine, sources, 38
- Viral vaccines, 583–585
- Viscosity
- definition, 615
 - measurement, in rheology, 452
 - of ophthalmic preparations, 615–616
 - in rheology, 452
 - of suspensions, 449
 - temperature and, 615
- Vitamin, 762
- Volume
- measurement techniques, 778–780
 - in quantitative product strength, 774–775
 - units
 - in apothecary system, 770, 772
 - intersystem conversion of, 773
 - metric system, 770–773
- Volume of distribution, drug, 202
- W**
- Wafer, 769
- Warfarin
- drug interactions, 488
 - protein binding of, 204
 - volume of distribution, 202
- Water
- bacteriostatic, for injection, 515
 - distillation, 403
 - hydrogen bonds in, 399
 - for injection, 515
 - ion exchange purification, 403
 - purified, 402–403
 - radiolabeled, in positron emission tomography, 654
 - requirements, in parenteral nutrition, 515
 - reverse osmosis, 404
 - sterile
 - for injection, 533
 - in irrigation solutions, 571
 - viscosity, 615–616
- Water channels, 169
- Water-in-oil emulsions, 465
- Water-miscible bases, for suppositories, 373–374
- Waterproofing, of tablets, 285
- Water-removable bases, 318
- Water-removable bases, for ointment, 318
- Water-soluble bases
- for ointments, 318
 - for suppositories, 373–374
- Weak acids, solubility, 398, 399t
- Weak bases, solubility, 399t
- Wecobee bases, 373
- Weight
- body, dosage determination and, 64
 - of capsules, variation of, 253–254
 - measurement techniques, 777
 - in quantitative product strength, 774–775
 - units
 - in apothecary system, 777
 - in avoirdupois system, 773
 - intersystem conversion of, 773
 - metric system, 770–773
 - vs.* volume, in solutions, 404
- Well-closed container, 88

Wet granulation method, for
 tablet manufacture, 276–279,
 277–278

Wet gum (English) method, for
 emulsion preparation, 473

Wet method, for effervescent granule
 preparation, 234–235

Wetting agents
 for emulsions, 466
 HLB values, 470t
 for suspensions, 469

Wetting solutions, for contact lenses, 623

White ointment, 317

White petrolatum, 317

Witepsol bases, 373

Women
 in clinical studies, 54
 dosage determination for, 64

World Health Organization,
 International Pharmacopeia, 12

Wurster process, for tablet coating, 289

X

Xanthine alkaloid, 762

Xanthine oxidase inhibitor, 762

Xerogels, 479

X-ray contrast medium, 762

Xylitol, in chewable tablets, 283

Y

Yellow fever vaccine, 589t

Yellow ointment, 317

Yttrium-90, 647–648, 648

Z

Zanamivir for inhalation, 229

Zero order rate reactions, 135c–137c

Zinc gelatin, 325

Zinc oxide paste, 325

Zinc oxide–eugenol mixture, 434

Z-track injection technique, 512

Zydis system, for rapidly-dissolving
 tablets, 267